MedTrace Logo

A Trial Investigating NN1218 in Subjects With Type 1 Diabetes

NCT01121289 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2013-12-10

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 diabetes.

Conditions

Interventions

DRUG

NN1218

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

insulin aspart

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

NN1218

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

NN1218

0.4 U/kg body weight injected subcutaneously (under the skin)

DRUG

NN1218

0.2 U/kg body weight injected subcutaneously (under the skin)

DRUG

NN1218

0.2 U/kg body weight injected subcutaneously (under the skin)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121289 on ClinicalTrials.gov